{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Board Pearls","title":"Chapter 22, Ep 3 of 3: A1AT, CF Liver Disease, PCLD, and Cholestatic Syndromes","html":"","width":"100%","height":180,"duration":948,"description":"Episode three closes the chapter with the four inherited liver diseases beyond the metal pair: alpha-one antitrypsin deficiency, cystic-fibrosis-associated liver disease, polycystic liver disease, and the familial cholestatic syndromes. The unifying move is that mechanism predicts therapy in each one, and each carries a distinct board trap. Alpha-one antitrypsin is the two-organ split where augmentation rescues the lung and does nothing for the liver; CF liver disease is one causal chain treated at three points; polycystic liver disease is synthetic-function-preserved mass effect; and the cholestatic syndromes split by the GGT pattern and cancer risk. Ileal bile acid transporter inhibitors, CFTR modulators, and the MELD exception anchor the modern management.\n \nTopics covered\n\nAlpha-one antitrypsin two-organ split\nPiZZ, the null genotype, and PAS-diastase-resistant globules\nAugmentation and NSAID treatment traps\nCF-associated liver disease and CFTR modulators\nPolycystic liver disease and the MELD exception\nFamilial cholestatic syndromes and the GGT split\nCancer risk by mechanism\nIBAT inhibitors and pruritus therapy\nAlagille syndrome\n \n \nKey decisions\n\nIn PiZZ alpha-one antitrypsin deficiency, IV augmentation restores circulating anti-elastase and slows lung decline but does nothing for the liver, because hepatic injury is from intracellular polymer, not circulating deficiency.\nAvoid NSAIDs in PiZZ patients because they increase hepatic alpha-one antitrypsin synthesis and worsen the polymer load; diagnose by phenotyping or genotyping, not the level alone, since it is an acute-phase reactant.\nThe null genotype causes severe early emphysema with normal liver enzymes because no protein is made to accumulate, while PiZZ biopsy shows PAS-positive, diastase-resistant periportal globules.\nIn cystic-fibrosis-associated liver disease, treat at three points: ursodeoxycholic acid downstream, fat-soluble vitamins in the middle, and CFTR modulators upstream, with triple...","thumbnail_url":"https://img.transistorcdn.com/-FuAdDBcPDLhEoUmroZKtOBRvuBn_FHPpYlh41hOnU4/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9iNzlh/ZTU4Y2MzNWExMjQ5/MjA5OWMwMmI3ZTk5/NGFiZS5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}